|

GC012F Injection Clinical Trials

3 actively recruiting trials

No change since June 2026

Also known as: AZD0120, CD19-BCMA CAR-T cells

Pipeline

Early 1: 2Phase 1: 1

Top Sponsors

  • RenJi Hospital1
  • Gracell Biotechnologies (Shanghai) Co., Ltd.1
  • Daishi Tian1

Indications

  • Cancer2
  • Relapsed/Refractory AL Amyloidosis1
  • Lupus1
  • CAR T Cell Therapy1
  • Generalized Myasthenia Gravis (gMG)1

Other3 trials

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
Early 1
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Early 1
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.